Claims
- 1. A pharmaceutical composition for the transdermal systemic administration of a pharmaceutically active agent in the form of an adhesive plaster or patch comprising a cover layer and a drug reservoir, wherein said composition comprises in a polymer matrix a homogeneous dispersion of active agent particles or a solution of active agent, said active agent being selected from the group consisting of bopindolol, tizanidine, clemastine and ketotifen, and being present in said reservoir comprising an acrylate/methacrylate polymer containing cationic ester groups.
- 2. A pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent in a reservoir comprising a polyacrylate polymer containing cationic ester groups, said pharmacologically active agent being selected from the group consisting of bopindolol, tizanidine, clemastine and ketotifen.
- 3. A composition according to claim 2 wherein the polymer is an acrylate/methacrylate polymer.
- 4. A composition according to any one of claims 1, 2 or 3 wherein the polymer contains trimethylaminoethyl ester groups.
- 5. A composition according to claim 1 in the form of an adhesive plaster or patching comprising a) a cover layer, b) a drug reservoir comprising 1 to 10 layers of a homogeneous dispersion of active agent particles or a solution of active agent in a polymer matrix, and d) an adhesive layer, reservoir c) being located between layers a) and d).
- 6. A composition of claim 1 comprising Bopindolol in free base form or in the form of an acid addition salt, in an acrylate/methacrylate polymer (A), containing trimethylaminoethyl ester groups, and a non-swellable acrylate resin (B), in a weight ratio of (A) to (B) of from 1:0.5 to 1:10.
- 7. A pharmaceutical composition according to claim 1, characterized by a skin penetration flux of at least 0.3 micrograms per cm.sup.2 per hour, when measured through isolated rat skin.
- 8. A pharmaceutical composition according to claim 7, characterized by a skin penetration flux of at least 0.8 micrograms per cm.sup.2 per hour.
Parent Case Info
This is a continuation of application Ser. No. 07/804,630, filed Dec. 9, 1991, now abandoned, which in turn is a continuation of application Ser. No. 07/597,470, filed Oct. 3, 1990, now abandoned, which in turn is a continuation of application Ser. No. 07/298,457, now abandoned, filed Jan. 18, 1989, which in turn is a continuation of application Ser. No. 07/096,571, now abandoned, filed Sep. 3, 1987, which in turn is a continuation of application Ser. No. 06/740,917, filed May 31, 1985, which is now abandoned.
US Referenced Citations (11)
Foreign Referenced Citations (10)
Number |
Date |
Country |
0013606 |
Jul 1980 |
EPX |
0072251 |
Feb 1983 |
EPX |
2514642 |
Apr 1983 |
FRX |
2005084 |
Aug 1970 |
DEX |
2913752 |
Dec 1979 |
DEX |
3204551 |
Aug 1983 |
DEX |
0206519 |
Dec 1983 |
JPX |
0025320 |
Feb 1984 |
JPX |
2098865 |
Dec 1982 |
GBX |
8300092 |
Jan 1983 |
WOX |
Non-Patent Literature Citations (16)
Entry |
Derwent 84014240 1983. |
Derwent 84071329 1984. |
Derwent 84104847 1984. |
Derwent 84021059 1983. |
Derwent 83741952 1983. |
Derwent 84148575 1984. |
Derwent 40807U 1973. |
Derwent 84133853 1984. |
Derwent 72524 1982. |
Derwent 71521T 1972. |
Derwent 87537V 1974. |
Derwent 66312C 1980. |
Derwent 72017T 1972. |
Derwent 73601D 1981. |
Derwent 75592D 1981. |
Chemical Abstracts No. 97:156157 1982. |
Continuations (5)
|
Number |
Date |
Country |
Parent |
804630 |
Dec 1991 |
|
Parent |
597470 |
Oct 1990 |
|
Parent |
298457 |
Jan 1989 |
|
Parent |
96571 |
Sep 1987 |
|
Parent |
740917 |
May 1985 |
|